The bleeding safety of the novel oral anticoagulant (NOAC) ‘Eliquis (apixaban)’ was reaffirmed through clinical practice guidelines of major academic societies.

On the 12th, BMS Korea and Pfizer Korea announced that they have hosted a ‘VMC Master of Masters Webinar’ on the 11th to share the latest advances in preventive therapies for atrial fibrillation and Eliquis’ effect and safety with healthcare professionals in Korea.

The webinar was prepared to share the latest advances in stroke prevention for atrial fibrillation patients by sharing the revised clinical practice guidelines from major international societies, and highlighted the stroke prevention effect and bleeding safety of